Composition and method for the treatment of obesity

Abstract

A composition formulated from sunflower, including Helianthus annulus and methods for use of the composition for treating obesity in a subject.

1 . A composition for modulating body weight in a subject comprising 42.50±2.5% w/w chlorogenic acid. 
     
     
         2 . The composition of  claim 1 , wherein the composition comprises at least one of 3CQA, 5CQA, 4 CQA, and Di CQA. 
     
     
         3 . The composition of  claim 1 , wherein the composition comprises a chlorogenic isomer selected from the group consisting of about 4.1±1.42% w/w 3CQA, about 28±4.65% w/w 5CQA, about 6.5±2.25 w/w 4 CQA, about 0.84±0.26 w/w 3,4 Di CQA, about 1.23±0.34 w/w 3,5 Di CQA, and about 1.85±0.42 w/w 4,5 Di CQA. 
     
     
         4 . The composition of  claim 1 , wherein the composition comprises (i) about 4.1±1.42% w/w 3CQA, (ii) about 28±4.65% w/w 5CQA, (iii) about 6.5±2.25 w/w 4 CQA, (iv) about 0.84±0.26 w/w 3,4 Di CQA, (v) about 1.23±0.34 w/w 3,5 Di CQA, and (vi) about 1.85±0.42 w/w 4,5 Di CQA. 
     
     
         5 . The composition of  claim 1 , wherein the composition is formulated from  Helianthus annuus.    
     
     
         6 . The composition of  claim 1 , wherein the composition has an antioxidant scavenging activity of about 87.88% at concentration of about 100 μg/ml as determined by DPPH assay. 
     
     
         7 . The composition of  claim 1 , wherein the composition has a superoxide scavenging activity of about 80.41% at concentration of about 100 μg/ml. 
     
     
         8 . The composition of  claim 1 , wherein the composition has total antioxidant activity of about 18.59 equivalents of ascorbic acid at a concentration of about 100 μg/ml. 
     
     
         9 . The composition of  claim 1 , wherein the composition has DNA scission protective effect of about 91.82% at a concentration of about 100 μg/ml. 
     
     
         10 . The composition of  claim 1 , wherein the composition inhibits lipase activity by at least 40% at a concentration of about 100 μg/ml. 
     
     
         11 . A method for modulating body weight in a subject comprising administering to the subject a composition comprising (i) 4.1±1.42% w/w 3CQA, (ii) 28±4.65% w/w 5CQA, (iii) 6.5±2.25 w/w 4 CQA, (iv) 0.84±0.26 w/w 3,4 Di CQA, (v) 1.23±0.34 w/w 3,5 Di CQA, and (vi) 1.85±0.42 w/w 4,5 Di CQA. 
     
     
         12 . The method of  claim 11 , wherein the composition inhibits pancreatic lipase activity in the subject. 
     
     
         13 . The method of  claim 11 , wherein modulating body weight in the subject comprises preventing or inhibiting weight gain in the subject. 
     
     
         14 . The method of  claim 11 , wherein modulating body weight in the subject comprises reducing body weight in the subject. 
     
     
         15 . The method of  claim 11 , wherein the subject is obese. 
     
     
         16 . The method of  claim 11 , wherein the subject is overweight. 
     
     
         17 . The method of  claim 11 , wherein the composition is administered to the subject orally, buccally, sub-lingually, parenterally, intravenously, intravaginally, rectally, or by inhalation. 
     
     
         18 . The method of  claim 11 , wherein the composition is a powder, liquid, pill, tablet, pellet, capsule, thin film, solution, spray, syrup, linctus, lozenge, pastille, chewing gum, paste, suspension, emulsion, gel, drop, buccal patch, bead, gummy, gel, or sol. 
     
     
         19 . The method of  claim 11 , wherein the composition inhibits lipase activity by at least 40% at a concentration of about 100 μg/ml in vitro.